<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="142802">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741584</url>
  </required_header>
  <id_info>
    <org_study_id>PA_memory_01</org_study_id>
    <nct_id>NCT01741584</nct_id>
  </id_info>
  <brief_title>Effects of Physical Activity on the Brain in Parkinson's Disease (PD)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to investigate whether exercise improves cognitive and motor
      functions in Parkinson's disease. To test this hypothesis, the researchers study general
      brain functions in subjects with PD during a 6-months exercise program.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2010</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>UPDRS motor score</measure>
    <time_frame>Prior to intervention and after 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional/Structural brain changes</measure>
    <time_frame>Prior to intervention and after 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma biomarkers</measure>
    <time_frame>Prior to intervention and after 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive Function based on neuropsychological test-performance</measure>
    <time_frame>Prior to intervention and after 6 months of intervention</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>stationary bike exercise</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of exercise (60% of anaerobic threshold)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aerobic</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>6 months of exercise &lt;30% anaerobic threshold</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>stationary bike exercise</intervention_name>
    <arm_group_label>stationary bike exercise</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>aerobic</intervention_name>
    <arm_group_label>aerobic</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  UPDRS &lt;15

          -  L-DOPA responsive

          -  &lt;5 yrs since diagnosis

        Exclusion Criteria:

          -  severe other diseases

          -  MMSE &lt; 26

          -  treatment with psychiatric medication
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Agnes Flöel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charite University, Berlin, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Lesemann, MD</last_name>
    <phone>+49 30 450 560 140</phone>
    <email>anne.lesemann@charite.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Neurology, Charité Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Lesemann, MD</last_name>
      <phone>+49 30 450 560 140</phone>
      <email>anne.lesemann@charite.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 28, 2014</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Agnes Flöel</investigator_full_name>
    <investigator_title>Prof. Dr. med. Agnes Floeel</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
